Foghorn Therapeutics (FHTX) Receivables - Other (2021)

Foghorn Therapeutics (FHTX) recorded quarterly Receivables - Other of $300.0 million in Q4 2021.

Foghorn Therapeutics (FHTX) Receivables - Other (2021) Analysis & Trends

Foghorn Therapeutics' Receivables - Other history runs 1 years deep, the most recent figure standing at $300.0 million for Q4 2021.

In Q4 2021, Receivables - Other changed N/A year-over-year to $300.0 million; the TTM figure through Dec 2021 stood at $300.0 million (changed N/A YoY), while the FY2021 annual figure was $300.0 million, changed N/A from the prior year.
Receivables - Other was $300.0 million for Q4 2021 at Foghorn Therapeutics.
In the past five years, Receivables - Other ranged from a high of $300.0 million in Q4 2021 to a low of $300.0 million in Q4 2021.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn
9	Abivax	91.96 Bn	91.96 Bn	-
10	Foghorn Therapeutics	282.33 Mn	193.42 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2021	300.00 Mn
Dec 31, 2021	300.00 Mn